A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson’s disease

Wang, Rui; Pang, Shu-Chao; Li, Jingya; Li, Chan-lian; Liu, Jun-miao; Wang, Yuming; Chen, Mei‐Ling; Li, Yubo

doi:10.1007/s00216-023-04520-1

Cited by 7 publications

(3 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathology of PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of α-synuclein in Lewy bodies. α-Synuclein encoded by SCNA has a role in the cell membrane interactions, dopamine metabolism and transportation of the vesicles in the central nervous system (CNS) (Wang et al, 2023). Atypical parkinsonism (APD) consists of different variants such as corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), dementia with Lewy Bodies (DLB), vascular parkinsonism (VaP) and multiple system atrophy (MSA) (Levin et al, 2016).…”

Section: Pea Studies In Parkinson' S Diseasementioning

confidence: 99%

Proximity extension assay‐based proteomics studies in neurodegenerative disorders and multiple sclerosis

Arioz,

Cotuk,

Yaka

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

Neurodegenerative diseases impact the structure and operation of the nervous system, causing progressive and irreparable harm. Efforts for distinguishing neurodegenerative diseases in their early stages are continuing. Despite several biomarkers being identified, there is always search for more accurate and abundant ones. Additionally, it can be difficult to pinpoint the precise neurodegenerative disorder affecting a patient as the symptoms of these conditions frequently overlap. Numerous studies have shown that pathological changes occur years before clinical signs appear. Therefore, it is crucial to discover blood‐based biomarkers for neurodegenerative diseases for easier and earlier diagnosis. Proximity extension assay is a unique proteomics method that uses antibodies linked to oligonucleotides for quantifying proteins with real‐time PCR. Proximity extension assay can identify even low‐quantity proteins using a small volume of specimens with increased sensitivity compared to conventional methods. In this article, we reviewed the employment of proximity extension assay technology to detect biomarkers or protein profiles for several neurodegenerative diseases.

show abstract

Section: Pea Studies In Parkinson' S Diseasementioning

confidence: 99%

Proximity extension assay‐based proteomics studies in neurodegenerative disorders and multiple sclerosis

Arioz,

Cotuk,

Yaka

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…[5] Current methods for 𝛼-syn oligomers detection primarily rely on in vitro approaches. [6] These methods include protein misfolding cyclic amplification, [7] enzyme-linked immunosorbent assays, [8] fluorescence resonance energy transfer assays, [9] and electrochemical methods. [10] However, these approaches are largely invasive and lack intuitiveness, constraining their applications in vivo.…”

Section: Introductionmentioning

confidence: 99%

Alpha‐Synuclein Oligomers Driven T1–T2 Switchable Nanoprobes for Early and Accurate Diagnosis of Parkinson's Disease

Chen,

Liang,

Wang

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

The alpha‐synuclein (α‐syn) oligomers hold a central role in the pathology of Parkinson's disease (PD). Achieving accurate detection of α‐syn oligomers in vivo presents a promising avenue for early and accurate diagnosis of PD. Magnetic resonance imaging (MRI), with non‐invasion and exceptional tissue penetration, offers a potent tool for visualizing α‐syn oligomers in vivo. Nonetheless, ensuring diagnostic specificity remains a formidable challenge. Herein, a novel MRI probe (ASOSN) is introduced, which encompasses highly sensitive antiferromagnetic nanoparticles functionalized with single‐chain fragment variable antibodies, endowing it with the capacity for discerning recognition and binding to α‐syn oligomers and triggering a switchable T1–T2 MRI signal. Significantly, ASOSN possesses the unique capability to accurately discriminate α‐syn oligomers from neuroinflammation in vivo. Moreover, ASOSN facilitates the non‐invasive and precise visualizing of endogenous α‐syn oligomers in living systems. This innovative design heralds the development of a non‐invasive visualization strategy for α‐syn oligomers, marking a pivotal advancement for early and accurate diagnosis of PD.

show abstract

“…α-Syn is a presynaptic protein that is the major constituent protein of Lewy bodies, the hallmark of Parkinson’s disease (PD) [ 4 , 5 ]. Accumulations of α-syn were found in the brain of patients with AD [ 6 , 7 , 8 , 9 ], as well as in patients with synucleinopathies, such as PD, dementia with Lewy bodies (DLB) [ 10 , 11 ], and multiple system atrophy [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A2A Adenosine Receptor Useful in Neurodegenerative Disorders

et al. 2023

View full text Add to dashboard Cite

Currently, the number of patients with neurodegenerative pathologies is estimated at over one million, with consequences also on the economic level. Several factors contribute to their development, including overexpression of A2A adenosine receptors (A2AAR) in microglial cells and up-regulation and post-translational alterations of some casein kinases (CK), among them, CK-1δ. The aim of the work was to study the activity of A2AAR and CK1δ in neurodegeneration using in-house synthesized A2A/CK1δ dual anta-inhibitors and to evaluate their intestinal absorption. Experiments were performed on N13 microglial cells, which were treated with a proinflammatory CK cocktail to simulate an inflammatory state typical of neurodegenerative diseases. Results showed that the dual anta-inhibitors have the ability to counteract the inflammatory state, even if compound 2 is more active than compound 1. In addition, compound 2 displayed an important antioxidant effect similar to the reference compound ZM241385. Since many known kinase inhibitors are very often unable to cross lipid bilayer membranes, the ability of A2A/CK1δ double anta-inhibitors to cross the intestinal barrier was investigated by an everted gut sac assay. HPLC analysis revealed that both compounds are able to cross the intestinal barrier, making them promising candidates for oral therapy.

show abstract

A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson’s disease

Cited by 7 publications

References 118 publications

Proximity extension assay‐based proteomics studies in neurodegenerative disorders and multiple sclerosis

Proximity extension assay‐based proteomics studies in neurodegenerative disorders and multiple sclerosis

Alpha‐Synuclein Oligomers Driven T1–T2 Switchable Nanoprobes for Early and Accurate Diagnosis of Parkinson's Disease

Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A2A Adenosine Receptor Useful in Neurodegenerative Disorders

Contact Info

Product

Resources

About